ATAI Life Sciences N.V (NASDAQ:ATAI)’s traded shares stood at 1.83 million during the last session, with the company’s beta value hitting 1.18. At the close of trading, the stock’s price was $1.65, to imply a decrease of -4.62% or -$0.08 in intraday trading. The ATAI share’s 52-week high remains $2.85, putting it -72.73% down since that peak but still an impressive 37.58% since price per share fell to its 52-week low of $1.03.
Analysts have given a consensus recommendation of Buy for ATAI Life Sciences N.V (ATAI), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give ATAI a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.15.
ATAI Life Sciences N.V (NASDAQ:ATAI) trade information
After registering a -4.62% downside in the last session, ATAI Life Sciences N.V (ATAI) has traded red over the past five days. The 5-day price performance for the stock is -19.12%, and 11.49% over 30 days. With these gigs, the year-to-date price performance is 24.06%.
The extremes give us $6 and $6 for target low and target high price respectively. As such, ATAI has been trading -263.64% off suggested target high and -263.64% from its likely low.
ATAI Life Sciences N.V (ATAI) estimates and forecasts
The rating firms project that company’s revenue will grow 159.03% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is 250k.
ATAI Dividends
ATAI Life Sciences N.V has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
The next major institution holding the largest number of shares is MORGAN STANLEY with 2.72 million shares, or about 1.7111% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $3.62 million.
We also have iShares Biotechnology ETF and Morgan Stanley Inst Fund Inc-Inception Port as the top two Mutual Funds with the largest holdings of the ATAI Life Sciences N.V (ATAI) shares. Going by data provided on Nov 30, 2024 , iShares Biotechnology ETF holds roughly 771.79 shares. This is just over 0.46% of the total shares, with a market valuation of $1.27 million. Data from the same date shows that the other fund manager holds a little less at 511.99, or 0.31% of the shares, all valued at about 0.84 million.
